09.07.2013 • NewsBever PharmaceuticalPharmaPharmstandard

Russia’s Pharmstandard To Spin Off Over-The-Counter Business

Pharmstandard, Russia's leading drugmaker has started steps to spin off its over-the-counter medicines business, it said on Monday.

The Russian company, majority owned by businessmen Viktor Kharitonin and Egor Kulkov, said in a separate statement that it is planning to buy a Singapore-based company called Bever Pharmaceutical in a deal valued at $630 million. It gave no further details about Bever's business or whether the two transactions are connected.

The separation of its over-the-counter business will be into a separate legal entity, the company said, but gave no further details about the structure of the new company or whether it would be listed. The company said it would hold a conference call on Wednesday to give more details of the spin-off. Pharmstandard generated 51 billion roubles ($1.55 billion) in 2012 sales, including its own drugs and third-party products.

Sales of drugs produced by Pharmstandard rose 3% to 20 billion roubles, with the over-the-counter segment contributing 15 billion roubles - a year-on-year fall of 4.5%. Revenues from prescription medicines rose 33% to about 6 billion roubles. A report in June said that Pharmstandard's over-the-counter business could be valued at around $2.5 billion - around the same as its market capitalisation.

Pharmstandard's shares are traded in Moscow and as depositary receipts in London. Its London-listed shares are trading around 38% higher than the $14.55 at which it was priced when it went public in May 2007.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.